• Home
  • Search Results

Research Studies

UNC-Chapel Hill Division of Hematology

24 studies match your search
By physician referral or invitation only

Testing the Usability of a Patient-Centered Tool

We are developing a computer-based tool for people who have cancers of the blood, bone marrow, and lymph nodes. This tool will help us understand what is most important to patients when it comes to the results of their treatment. We are looking for healthy volunteers (those without cancer) to help us test the usability of this tool.

Age & Gender
  • 21 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Healthy Volunteer or General Population
By physician referral or invitation only

Evaluating coagulation activation and the impact of iron status in patients with Hereditary Hemorrhagic Telangiectasia (HHT)

The purpose is to evaluate coagulation activation and the impact of iron status in patients with Hereditary Hemorrhagic Telangiectasia (HHT). Participants on this study will include patients with HHT, patients with iron deficiency +/- anemia but without HHT, and healthy volunteers The study team will procure single and/or serial blood samples from participants and assess various markers of hemostasis and activation of coagulation, and host iron status.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female
Study Interest
  • Blood Conditions
  • Healthy Volunteer or General Population
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

ARGX-113-ITTP-PILOT

The primary objective of the study is to evaluate the safety and feasibility of treating patients with a history of iTTP with efgartigimod, an FcRn inhibitor that reduces IgG autoantibodies, including those responsible for ADAMTS13 depletion.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female
Study Interest
  • Rare Diseases
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

Mitapivat for SCD Nephropathy

To evaluate the effect of mitapivat on albumin creatinine ratio (ACR) response in subjects with sickle cell disease (SCD) and nephropathy

Age & Gender
  • 18 years ~ 65 years
  • Male, Female, Gender Inclusive
Study Interest
  • Blood Conditions
  • Genetics and Genetic Disorders
  • Minority Health
  • Rare Diseases
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

GRNDaD

To have a well phenotyped cohort of people with sickle cell disease in order to examine risk factors for end organ disease through the creation of a multi-site registry and to develop a repository for the long-term storage of patient samples (whole blood, peripheral blood, serum) along with corresponding demographic and clinical information to allow for clinical and laboratory correlations.

Age & Gender
  • 0 years ~ 0 years
  • Male, Female, Gender Inclusive
Study Interest
  • Blood Conditions
  • Minority Health
  • Pain
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only
Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Blood Conditions
  • Rare Diseases
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

EMICIZUMAB IN PATIENTS WITH ACQUIRED HEMOPHILIA A

Purpose: Evaluate the efficacy of prophylactic Emicizumab administered on a scheduled basis to prevent bleeds in patients with acquired hemophilia A (AHA).

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Rare Diseases
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

AMC-114 - Paclitaxel or Liposomal Doxorubicin for HIV-positive Persons with Kaposi Sarcoma

This study is being done to answer the following question: Do two different anti-cancer drugs, paclitaxel (PTX) and pegylated liposomal doxorubicin (PLD) have similar effects on treating KS in PLWH in sub-Saharan Africa? We are doing this study because we want to find out if one of these approaches, PTX or PLD, is better than the other for KS. Both drugs may be given as part of the usual approach for your KS. The usual approach is defined as care most people get for KS.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Sarcoma (bone and soft tissue))
  • HIV/AIDS
Visit Location
100% Remote (online, phone, text)
Not currently enrolling

Leukemia

The main purpose of this clinical research study is to assess the safety, tolerability, efficacy (the ability of the study drug to produce the desired anti cancer effect), PK] and PD of GHF009X2101 the study drug in patients with relapsed or refractory hematologic malignancies including AML, CLL, SLL or other lymphomas [including other leukemia].

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Leukemia)
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

Identifying challenges and stressors related to accessing central venous catheters (CVCs) for treatment infusions: a pilot study

The purpose of this research study is to improve safety measures and reduce stressors associated with lumen hub-clave seizures when caring for patients with CVCs. The primary outcome of the pilot study is to document the types and frequency of workarounds employed, current disinfection techniques, and the stressors of those caring for and accessing CVCs.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Stomach, Digestion and Gut Health
  • Immune System/Infections
  • Opinions and Perceptions
  • and 3 more
Visit Location
100% Remote (online, phone, text)
Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research